Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary At its 34th Annual General Meeting of Shareholders, Celltrion approved all agenda items as originally proposed, including the financial statements, a cash dividend of KRW 750 per common share, a 5% stock dividend, reduction of capital reserves, and the re-election of Seo Jung-jin as director. 📊…

Read More “[Disclosure] Celltrion (068270) – Results of Annual General Meeting of Shareholders / 2025-03-25” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion decided to acquire 268,385 treasury common shares worth approximately KRW 50.0B through on-market purchases to stabilize its stock price and enhance shareholder value, with plans to retire all acquired shares after completion. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Read More “[Disclosure] Celltrion (068270) – Treasury Share Acquisition Decision / 2025-03-21” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion submitted an Investigational New Drug (IND) application to South Korea’s Ministry of Food and Drug Safety (MFDS) for a global Phase 3 clinical trial of CT-P44, a Darzalex biosimilar candidate, targeting patients with refractory or relapsed multiple myeloma. 📊 Key Disclosure Content & Financial Highlights…

Read More “[Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P44 (Darzalex Biosimilar) in South Korea / 2025-03-20” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced its Corporate Value-up Plan, targeting KRW 5.0T in revenue for 2025, over 30% average annual revenue growth and ROE of 7% or higher by 2027, alongside a 3-year average shareholder return ratio target of 40%. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s…

Read More “[Disclosure] Celltrion (068270) – Corporate Value-up Plan / 2025-03-18” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen signed an exclusive license agreement with a subsidiary of AstraZeneca for its human hyaluronidase technology (ALT-B4), featuring an upfront payment of KRW 36.37B (US$ 25M) and milestone payments of up to KRW 1.05T (US$ 725M), bringing the total potential contract value up to KRW 1.09T…

Read More “[Disclosure] ALTEOGEN (196170) – Execution of Exclusive License Agreement for Human Hyaluronidase Core Technology (ALT-B4) / 2025-03-17” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen signed an exclusive license agreement with a subsidiary of AstraZeneca for its human hyaluronidase technology (ALT-B4), featuring an upfront payment of KRW 29.10B (US$ 20M) and milestone payments of up to KRW 843.78B (US$ 580M), bringing the total potential contract value up to KRW 872.88B…

Read More “[Disclosure] ALTEOGEN (196170) – Execution of Exclusive License Agreement for Human Hyaluronidase Core Technology (ALT-B4) / 2025-03-17” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received and submitted its Audit Report for FY2024 (34th fiscal term) from Samil PwC, obtaining an ‘Unqualified’ audit opinion for both consolidated and separate financial statements. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Final Approval of Financial Statements…

Read More “[Disclosure] Celltrion (068270) – Submission of Audit Report / 2025-03-17” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen decided to convene its Annual General Meeting of Shareholders on March 31, 2025, to vote on key agenda items including the approval of financial statements, re-election of CEO Soon Jae Park, new appointment of Vice President Sang Lak Choi as Inside Director, appointment of Auditor,…

Read More “[Disclosure] ALTEOGEN (196170) – Resolution on Convocation of General Shareholders Meeting / 2025-03-14” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed that all agenda items presented at its 14th Annual General Meeting (AGM) of Shareholders—including approval of financial statements, amendments to the articles of incorporation, appointments of directors and audit committee members, and approval of director remuneration limits—were approved as originally proposed. 📊…

Read More “[Disclosure] Samsung Biologics (207940) – Results of Annual General Meeting of Shareholders / 2025-03-14” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion decided through a board resolution to retire 1,101,379 treasury common shares (book value of approximately KRW 184.3B) to stabilize its stock price and enhance shareholder value, with the retirement scheduled for March 25, 2025. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key…

Read More “[Disclosure] Celltrion (068270) – Share Retirement Decision / 2025-03-14” »